TM5509 60mg/day for 7 days TM5509 120mg/day for 7 days

2 trials

Sponsors

Tohoku university school of medicine, molecular medicine and therapy, Toshio Miyata, Tohoku University School of Medicine, Molecular Medicine and Therapy, Toshio Miyata

Conditions

Cord Blood TransplantationHematologic Malignancy

Phase 2

A phase II study to reveal safety and efficacy of TM5509 in cord blood transplantation

RecruitingJPRN-UMIN000018180

Tohoku university school of medicine, molecular medicine and therapy, Toshio MiyataCord Blood Transplantation

Start: 2015-07-10Target: 21Updated: 2026-06-29

A phase II trial to reveal safety and efficacy of TM5509 in allogeneic stem cell transplantation with TBI regimen

RecruitingJPRN-UMIN000018191

Tohoku University School of Medicine, Molecular Medicine and Therapy, Toshio MiyataHematologic Malignancy

Start: 2015-07-10Target: 15Updated: 2026-06-29